NRX PHARMACEUTICALS INC (NRXP) Stock Income Statement
USA - NASDAQ:NRXP - US6294442099 - Common Stock
2.4744 USD
-0.02 (-0.63%)
| TTM (2025-6-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 14.13M | 19.70M | 27.59M | 44.34M | 94.43M | |||
| Research and Development | 3.44M | 6.20M | 13.37M | 17.03M | 20.26M | |||
| Selling, General, and Administrative Expenses | 10.69M | 13.51M | 14.22M | 27.31M | 74.94M | |||
| Operating Income | -14.13M | -19.70M | -27.59M | -44.34M | -94.43M | |||
| Interest Income/Expense | 16.00K | -186.00K | 374.00K | 504.00K | 1.67M | |||
| Other Income/Expense | -16.03M | -4.31M | -2.69M | 4.08M | 20.94M | |||
| Non Recurring Items | -3.65M | -925.00K | -250.00K | 0 | -21.25M | |||
| Income Before Taxes | -33.79M | -25.13M | -30.15M | -39.75M | -93.06M | |||
| Income Tax | null | 0 | null | 0 | 0 | |||
| Net Income | -33.79M | -25.13M | -30.16M | -39.75M | -348.88M | |||
| EBITDA | null | -19.70M | -27.58M | -44.33M | -94.43M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.2072 | -2.3605 | -0.4 | -6.04 | -74.36 | |||
| Non GAAP EPS | -1.42 | -2.31 | -4 | null | null | |||
| Statistics | ||||||||
All data in USD